Generic Allegra (Fexofenadine) Detailed Reviews

On Aug. 20, the FDA approved oral estradiol ethanoate (Femtrace tablets, made by Filmmaker Chilcott PLC) for the assistance of menopausal vasomotor symptoms.
A secondary winding communication for vulvar-vaginal weakening was not granted.
The production will be available in 0.45-, 0.9-, and 1.8-mg pad of paper strengths.
Large Atom Hyaluronic Acid Gel (Hylaform Plus) Object for Seventh cranial nerve Wrinkles and Folds
On Oct. 13, the FDA approved a large-particle hyaluronic acid–based dermal tobacco (Hylan-B gel, also known as Hylaform Plus, made by Inamed Corp.) for the rebuke of moderate to severe nervus facialis wrinkles and folds.
The set is made up of a larger mean subatomic particle size of hyaluronic acid gel compared with the company’s previously approved dermal baccy (Hylaform, approved April 23), allowing for tending of the deepest wrinkles and optimal seventh cranial nerve contouring.
New Formulations: Donepezil (Aricept), Fexofenadine (Allegra-D), Levofloxacin (Levaquin), Famotidine (Fluxid)
On Oct. 19, the FDA approved an orally disintegrating dosage form of donepezil HCl (Aricept ODT, made by Eisai Medical Research) for the handling of mild to moderate Alzheimer’s-type dementia.
On Oct. 19, the FDA approved a 24-hour extended-release pad of paper form of fexofenadine HCl (Allegra-D 180 mg, made by Aventis Pharmaceuticals, Inc.) for the match of symptoms associated with seasonal allergic rhinitis in adults and children aged 12 geezerhood and older.
On Oct. 21, the FDA approved a once-daily oral method style of levofloxacin 25 mg/mL (Levaquin, made by Ortho-McNeil c/o United States President & Author Pharmaceuticals Investigation and Development) to facilitate management in somebody patients who have trouble swallowing tablets.
The fluoroquinolone antibiotic root is approved for all flow dose and intravenous levofloxacin indications.
On Sept. 24, the FDA approved a disintegrating dose conceptualization of famotidine (Fluxid, made by Schwarz Pharma, Inc.) for the discussion of ulcers and pathological hypersecretory circumstance.

Nov. 4, 2007 — The U.S. Food and Drug Association (FDA) has approved clindamycin foam 1% for the topical handling of acne; a disposable pen-like birth instrumentality for somatropin injection; estradiol salt to relieve the vasomotor symptoms of menopause; large-particle hyaluronic acid gel for thread deep wrinkles; orally disintegrating pad of paper formulations of donepezil HCl and famotidine; a once-daily oral solvent conceptualisation of levofloxacin; and a 24-hour extended-release style of fexofenadine HCl.
Clindamycin Foam 1% (Evoclin) for Acne
On Oct. 25, the FDA approved clindamycin 1% foam (Evoclin [formerly known as Actiza], made by Connetics Corp.) for once-daily topical coating in the intervention of acne vulgaris.
The drug dissolves rapidly upon communication channel with skin, leaving minimal component.
Clindamycin foam 1% is contraindicated in those with a humanistic discipline of sensibility to clindamycin or lincomycin, regional enteritis or ulcerative colitis, or antibiotic-associated colitis.
Premixed, Multidose, Disposable Pen for Somatropin Intromission (Norditropin NordiFlex)
On Oct. 13, the FDA approved a pen-like human activity orderliness with a new liquid state chemical compound of somatropin (rDNA) injectant (Norditropin NordiFlex, made by Novo Nordisk), indicated in the long-term tending of children with outgrowth unfortunate due to inadequate liquid body substance of endogenous vegetation hormone.
The premixed, prefilled, multidose, disposable pen is based on the company’s insulin bringing systems.
It is available in a 5 mg/1.5 mL size that delivers doses from 0.025 mg to 1.5 mg, and a 15 mg/1.5 mL size that delivers doses from 0.075 mg to 4.5 mg.

In the newly published immersion, hay symptom patients state treated at 11 centers throughout Switzerland and Germany received either Ze339 playing card second a day (totaling 8 milligrams), a single-daily 180-milligram pill of Allegra, or a medicament. The researchers reported that both chemical agent treatments were equally effective and more effective than vesper for relieving hay feverishness symptoms such as sneezing, bone crowding, and itchy eyes and/or nose. Both person treatments were also well tolerated. The findings were reported in the June number of the written material Phytotherapy Investigation. Area of Other Products Questioned Schapowal says he’s confident that the creation his set tested is safe. But he is less sure about unregulated herbal products containing butterbur that are sold in the U.S. “I wouldn’t take them,” he says. “Many of these products are derived from the root of the actor and there is no controlled refinement. They cannot be considered safe.” Allergist Brian Smart, MD, says that a “natural” direction for allergies and asthma would be salutation. But he adds that none of the alternative products widely used for this intent in the U.S. have been adequately tested. Smart is a spokesman for the Denizen School of Allergy, Asthma, and Immunology, which reported in 2003 that 17% of Americans try discourse for allergies had tried complementary and alternative medications. Butterbur, ephedra, grape vine seed solution, and endocrine gland excerption are some of the most widely used alternative therapies for hay feverishness and allergy. The making known concluded that none of the alternative products have been proven both safe and effective. “As an allergist I always salutation the possibleness of new therapies,” Smart tells WebMD. “But my enterprise is that these products are not regulated, so you really don’t know what you are getting. Even though a so-called cast production sounds safer, it may not be.”

Aug. 22, 2007 — An herbal Cartesian product derived from the leaves of the butterbur dodge was found to be as effective for treating hay pyrexia as a widely used antihistamine.
But concerns remain about the guard of unregulated products containing the role player infusion sold in the United States.
The Swiss immersion was the largest ever to examine butterbur for the management of allergies.
A amount of 330 participants receive either the butterbur-extract consequence Ze339, high doses of the antihistamine Allegra, or vesper.
Swiss herbal medicament business Zeller AG, which markets Ze339, sponsored the investigation.
The quantity is not sold in the United States, but other butterbur-extract products are.
Researcher Andreas Schapowal, MD, PhD, tells WebMD that this and other studies conducted by his investigation team show that the herbal trade good is both safe and effective.
He adds that because it is also nonsedating, it could be a good decision making for sept who mental object drowsiness when taking certain antihistamines.
Butterbur Used for Centuries
Butterbur (also known as blatterdock, flapperdock, or swimming stroke doc) is a works found throughout International organization and Asia and parts of National leader North American nation.
It has been used in herbal remedies for centuries and in commercial medicines in Collection for several decades.
In quality, the industrial plant does contain chemicals that are considered toxins and may be carcinogenic.
There have been isolated reports of serious viscus problems occurring in phratry who took butterbur preparations containing high levels of these chemicals.
Schapowal says the Cartesian product he tested is safe because it is derived exclusively from the heart-shaped leaves of the butterbur stratagem and not the root, as some other preparations are.
Plants are also especially cultivated to make the herbal merchandise.

Rx State: Whose Pick Should It Be? A careful questioning by the FDA of its legal somebody has persuaded Mark B. McClellan, MD, FDA executive, that the activeness has the person to religious sect pharmaceutical marketers to railway medications from medicine to OTC position. McClellan is likely to test that version as the FDA weighs forcing a difference in the state of the antihistamines Zyrtec, whose written document does not run out until 2007, and Allegra, under legal document extortion until 2011. Those directives could be followed by others moving contraceptives and heartburn treatments to OTC condition. Such orders would be a significant string of FDA major power and will likely be opposed strenuously by Pfizer and Aventis, the 2 companies that marketplace these medications. The thrust for such a shimmy is the uprising cost of black and white medications and efforts by MCOs and others to contain these costs. The legal return first-class honours degree came to the fore in 2001 when the FDA received a asking from WellPoint HealthNetworks in California to make Claritin, Allegra, and Zyrtec available OTC. After office officials signaled that they might parceling the substance, Schering-Plough agreed to make Claritin available OTC, and the condition cash became skilled workman in November 2002. Claritin was due to go off letters patent (in December 2002), and Schering-Plough had already refocused its promotional efforts on a newer, long-acting interpretation, Clarinex.

On Oct. 17, the FDA approved an expanded data point for iron sucrose shot (Venofer, made by American Trustee, Inc., under permission from Vifor International Inc.), allowing its use for the intervention of iron-deficiency genus Anemia in peritoneal dialysis-dependent patients with chronic kidney disease (CKD) who are receiving erythropoietin therapy.
The issue was previously approved for this reading in hemodialysis-dependent CKD patients receiving an erythropoietin, and predialysis CKD patients receiving or not receiving erythropoietin.
In peritoneal patients, iron sucrose is infused intravenously in tierce divided doses for a sum dose of 1000 mg during a 28-day geological period: two infusions of 300 mg for 1.5 time period 14 days apart, followed by one 400-mg instilment for 2.5 minute 14 days later.

New Fexofenadine (Allegra) Dosing Regimen for Idiopathic Urticaria
On Oct. 13, the FDA approved once-daily fexofenadine HCl (Allegra 180-mg tablets, made by Sanofi-Aventis Group), allowing its use in the artistic style of chronic idiopathic urticaria in grownup and pediatric patients aged 12 assemblage and older.
The previously recommended dosing regimen of fexofenadine was 60 mg twice daily.
Fexofenadine is indicated for use in adults and children aged six days and older to relieve symptoms associated with seasonal allergic rhinitis, and to delicacy uncomplicated skin manifestations of chronic idiopathic urticaria.
Support of the new regimen allows use of the 180-mg dose for both indications in patients aged 12 period of time and older.